Genprex Inc (GNPX)

[crudeoil24]

"Based in Cambridge, Mass., Dr. Pham will oversee the Company's clinical development program for its immunogene therapy, Oncoprex(TM), for non-small cell lung cancer. The company previously reported data from an interim analysis of nine evaluable patients enrolled in its Phase II clinical trial with Oncoprex in combination with erlotinib (Tarceva(R)) in late stage non-small cell lung cancer, which showed an overall disease control rate (stable disease, partial response or complete response) of 78 percent. One patient had a Complete Response, or CR under RECIST criteria. This patient was EGFR positive with a rare mutation not usually treated with a TKI and had disappearance of the lung primary tumor, as well as lung, liver, and lymph node metastases. The company also previously reported that preclinical studies with TUSC2 (formerly known as FUS1, the active anti-cancer agent in Oncoprex) in combination with a PD-1 checkpoint inhibitor in syngeneic mouse models demonstrated a significantly greater anti-tumor effect in lung cancer than either agent alone, which correlated with prolonged survival in mice.